依贝沙坦联合羟苯磺酸钙治疗30例糖尿病肾病效果剖析.docVIP

依贝沙坦联合羟苯磺酸钙治疗30例糖尿病肾病效果剖析 　　摘 要 目的：观察依贝沙坦联合羟苯磺酸钙治疗糖尿病肾病的临床疗效。方法：将60例糖尿病肾病患者随机分为观察组与对照组各30例。观察组患者给予依贝沙坦口服150 mg/d，联合羟苯磺酸钙分散片口服500 mg/次、3次/d进行治疗；对照组患者单纯给予依贝沙坦口服150 mg/d，两组疗程均为3个月，两组患者在疗程开始之前与疗程结束之日检测患者的血压和肾功能指标（尿b-微球蛋白、血清肌酐、尿素氮、24 h尿蛋白）等，并观察记录两组患者不良反应情况。结果：用药后，两组患者血压和肾功能指标均明显改善（P0.05）；与对照组相比，观察组患者上述指标降低幅度更明显。两组患者用药期间均未见明显骨髓抑制、肝肾损害等不良反应，患者有较好的依从性。结论：依贝沙坦联合羟苯磺酸钙治疗糖尿病肾病疗效显著，能发挥良好的降压、改善肾功能作用，优于单用依贝沙坦，且未见明显不良反应。 　　关键词 糖尿病肾病 联合用药 羟苯磺酸钙 依贝沙坦 　　中图分类号：R587.2 文献标识码：B 文章编号：1006-1533（2017）05-0015-03 　　Analysis of the effectiveness of irbesartan combined with calcium dobesilate in the treatment of 30 cases of patients with diabetic nephropathy 　　ZHOU Ruiqin*， CHEN Yan 　　（Division One of Internal Medicine， the Third People’s Hospital of Luohe City， Luohe 462000， China） 　　ABSTRACT Objective： To explore the clinical effect of irbesartan combined with calcium dobesilate in the treatment of diabetic nephropathy. Methods： Sixty cases of patients with diabetic nephropathy were randomly divided into an observation group and a control group with 30 cases each. The observation group was treated with 150 mg of irbesartan daily combined with 500 mg of calcium dobesilate dispersible tablets， 3 times a day while the control group was treated only with irbesartan， and the treatment was lasted for three months. The blood pressure， renal function indexes （urinary b-mini-globulin， serum creatinine， urea nitrogen and 24-hour urinary protein） and complications were compared. Results： After treatment， the blood pressure and renal function indexes were reduced in the two groups but more obviously in the observation group （P0.05）. Adverse reactions such as bone marrow suppression， liver and kidney damage were not found in the two groups and the patients had better compliance. Conclusion： Irbesartan plus calcium dobesilate for the treatment of diabetic nephropathy possesses clear efficacy， can decrease blood pressure and improve the renal function without significant adverse reactions. 　　KEY WOR